Die zukünftige Geschichte der Lepra

Einleitung

Jahrzehntelang vor allem im Umfeld der WHO wiederholte Ankündigungen einer baldigen Ausrottung der Lepra waren nie wissenschaftlich vertretbar. Für die „Eradikation“ fehlen die Voraussetzungen. Die Bezeichnung „Elimination“ für bloße Reduktion der Prävalenz unter 1:10 000 ist irreführend. Erreichbar ist nur Kontrolle der Lepra. Entdeckung und Behandlung aller Infizierten ist kaum möglich. Mehr Hoffnung knüpft sich an die Entwicklung von Impfungen. Aber möglicherweise werden sich von selbst genetische Anpassungen durchsetzen, die z. B. in Mitteleuropa schon im Beginn der Neuzeit die Lepra erlöschen ließen.

• Literatur

• 1 Silva CA, Danelishvili L, McNamara M et al. Interaction of Mycobacterium leprae with human airway epithelial cells: adherence, entry, survival, and identification of potential adhesins by surface proteome analysis. Infect Immun 2013; 81: 2645-2659
• 2 Naves MdeM, Ribeiro FA, Patrocinio LG et al. Bacterial load in the nose and its correlation to the immune response in leprosy patients. Lepr Rev 2013; 84: 85-91
• 3 Hundeiker M, Perusquia-Ortiz AM, Bassukas ID. El futuro de la lepra: Ilusiones y realidad. Dermatol Rev Mex 2013; 57: 491-495
• 4 Wennberg-Hilger KK. Das seuchenhafte Auftreten von Lepra in einigen Küstenregionen West-Norwegens im 19. Jahrhundert. Mit einem ergänzenden Bericht über die entsprechende Situation in Schweden. Med. Inaug.-Diss. Bonn: 2011
• 5 Agius-Ferrante A, Depasquale G, Bonnici E et al. The leprosy eradication-project of Malta. Z Tropenmed Parasitol 1973; 24 (Suppl. 01) 49-52
• 6 Briffa DV. 'Eradication' of leprosy from Malta. Lepr Rev 1987; 58: 87-89
• 7 Aranzazu N, Parra JJ, Cardenas M et al. Cojedes: a leprosy hyperendemic state. Int J Dermatol 2012; 51: 186-194
• 8 Alencar CH, Ramos AN Jr, Barbosa JC et al. Persisting leprosy transmission despite increased control measures in an endemic cluster in Brazil: the unfinished agenda. Lepr Rev 2012; 83: 344-353
• 9 Bassukas ID, Gaitanis G, Hundeiker M. Leprosy and the natural selection for psoriasis. Medical Hypotheses 2012; 78: 183-196
• 10 Singal A, Sonthalia S. Leprosy in post-elimination era in India: difficult journey ahead. Indian J Dermatol 2013; 58: 443-446
• 11 Han XY, Seo YH, Sizer KC et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008; 130: 856-864
• 12 Gillis TP, Scollard DM, Lockwood DN. What is the evidence that the putative Mycobacterium lepromatosis species causes diffuse lepromatous leprosy?. Lepr Rev 2011; 82: 205-209
• 13 Jessamine PG, Desjardins M, Gillis T et al. Leprosy-like illness in a patient with Mycobacterium lepromatosis from Ontario, Canada. J Drugs Dermatol 2012; 11: 229-233
• 14 Cole ST, Eiglmeier K, Parkhill J et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-1011
• 15 Monot M, Honoré N, Garnier T et al. On the origin of leprosy. Science 2005; 308: 1040-1042
• 16 Monot M, Honoré N, Garnier T et al. Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet 2009; 41: 1282-1289
• 17 Achtman M. Insights from genomic comparisons of genetically monomorphic bacterial pathogens. Philos Trans R Soc Lond B Biol Sci 2012; 367: 860-867
• 18 Meyers WM, Gormus BJ, Walsh GP. Nonhuman sources of leprosy. Int J Lepr Other Mycobact Dis 1992; 60: 477-480
• 19 Walsh GP, Meyers WM, Binford CH. Naturally acquired leprosy in the nine-banded armadillo: a decade of experience 1975-1985. J Leukoc Biol 1986; 40: 645-656
• 20 Truman R. Leprosy in wild armadillos. Lepr Rev 2005; 76: 198-208
• 21 Frota CC, Lima LN, Rocha AdaS et al. Mycobacterium leprae in six-banded (Euphractus sexcinctus) and nine-banded armadillos (Dasypus novemcinctus) in Northeast Brazil. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 209-213
• 22 Clark BM, Murray CK, Horvath LL et al. Case-control study of armadillo contact and Hansen's disease. Am J Trop Med Hyg 2008; 78: 962-967
• 23 Lane JE, Walsh DS, Meyers WM et al. Borderline tuberculoid leprosy in a woman from the state of Georgia with armadillo exposure. J Am Acad Dermatol 2006; 55: 714-716
• 24 Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998; 76 (Suppl. 02) 22-25
• 25 Mayr A. Eradikation und Tilgung von Seuchen. Dtsch Ärztebl 2006; 103 A: 3115-3118
• 26 Hart BE, Tapping RI. Genetic Diversity of Toll-like Receptors and Immunity to M. leprae Infection. J Trop Med
• 27 Fava V, Orlova M, Cobat A et al. Genetics of leprosy reactions: an overview. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 132-142
• 28 Cardoso CC, Pereira AC, de Sales MarquesC et al. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future Microbiol 2011; 6: 533-549
• 29 Boldt AB, Sanchez MI, Stahlke ER et al. Susceptibility to leprosy is associated with M-ficolin polymorphisms. J Clin Immunol 2013; 33: 210-219
• 30 Klatser PR, van Beers S, Madjid B et al. Detection of Mycobacterium leprae nasal carriers in populations for which leprosy is endemic. J Clin Microbiol 1993; 31: 2947-2951
• 31 Naves MdeM, Ribeiro FA, Patrocinio LG et al. Bacterial load in the nose and its correlation to the immune response in leprosy patients. Lepr Rev 2013; 84: 85-91
• 32 Turankar RP, Lavania M, Singh M et al. Dynamics of Mycobacterium leprae transmission in environmental context: Deciphering the role of environment as a potential reservoir. Infect Genet Evol 2012; 12: 121-126
• 33 Alter A, Grant A, Abel L et al. Leprosy as a genetic disease. Mamm Genome 2011; 22: 19-31
• 34 Fitness J, Tosh K, Hill AVS. Genetics of susceptibility to leprosy. Genes and Immunity 2002; 3: 441-453
• 35 Johnson CM, Lyle EA, Omueti KO et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007; 178: 7520-7524
• 36 Convit J, Gonzales CL, Rassi E. Estudios sobre lepra en el grupo étnico alemán de la Colonia Tovar, Venezuela. Internat J Leprosy 1952; 20: 185-193
• 37 Hohmann N, Voss-Böhme A. The epidemiological consequences of leprosy-tuberculosis co-infection. Math Biosci 2013; 241: 225-237
• 38 De Sales Marques C, Brito-de-Souza VN, Guerreiro LT et al. Toll-like Receptor 1 N248S Single-Nucleotide Polymorphism Is associated with leprosy risk and regulates immune activation during mycobacterial infection. J Infect Dis 2013; 208: 120-129
• 39 Lydakis C, Ioannidou D, Koumpa I et al. Development of lepromatous leprosy following etanercept treatment for arthritis. Clin Rheumatol 2012; 31: 395-398
• 40 De Freitas MR, Said G. Leprous neuropathy. Handb Clin Neurol 2013; 115: 499-514
• 41 Reinar LM, Forsetlund L, Bjrndal A et al. Interventions for skin changes caused by nerve damage in leprosy. Sao Paulo Med J 2013; 131: 210
• 42 Rodriguez G, Pinto R, Gomez Y et al. Pure neuritic leprosy in patients from a high endemic region of Colombia. Lepr Rev 2013; 84: 41-50
• 43 Sales AM, Campos DP, Hacker MA et al. Progression of leprosy disability after discharge: is multidrug therapy enough?. Trop Med Int Health 2013; 18: 1145-1153
• 44 Scollard DM. The biology of nerve injury in leprosy. Lepr Rev 2008; 79: 242-253
• 45 Scollard DM, Adams LB, Gillis TP et al. The Continuing Challenges of Leprosy. Clin Microbiol Rev 2006; 19: 338-381
• 46 Bretan O, De Souza LB, Lastória JC. Laryngeal lesion in leprosy and the risk of aspiration. Lepr Rev 2007; 78: 80-81
• 47 Pallagatti S, Sheikh S, Kaur A et al. Oral cavity and leprosy. Indian Dermatol Online J 2012; 3: 101-104
• 48 Sharp D. Leprosy lessons from old bones. Lancet 2007; 369: 808-809
• 49 Jacobson RR, Gatt P. Can leprosy be eradicated with chemotherapy? An evaluation of the Malta Leprosy Eradication Project. Lepr Rev 2008; 79: 410-415
• 50 WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 2012. (968) World Health Organization. 1-61 1 p following 61
• 51 Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World Health Organ 2005; 83: 230-235
• 52 Geluk A. Challenges in immunodiagnostic tests for leprosy. Expert Opin Med Diagn 2013; 7: 265-274
• 53 Naafs B. Treatment of Leprosy: science or politics?. Tropical Medicine & International Health 2006; 11: 268-278
• 54 Nsagha DS, Bamgboye EA, Assob JC et al. Elimination of leprosy as a public health problem by 2000 AD: an epidemiological perspective. Pan Afr Med J 2011; 9: 4 [Epub 2011 May 17]
• 55 Barreto JG, Guimarães LdeS, Frade MA et al. High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon Region. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 60-67
• 56 Beyene D, Aseffa A, Harboe M et al. Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega robi village, Ethopia. Epidemiol Infect 2003; 131: 841-848
• 57 Silva KKMBK, Gunasekera CN, Fernando J. Clinical and histological activity after short duration multidrug therapy for leprosy. Sri Lanka J Dermatol 2003; 7: 22-23
• 58 Duthie MS, Saunderson P, Reed SG. The potential for vaccination in leprosy elimination: new tools for targeted interventions. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 190-196
• 59 Degang Y, Nakamura K, Akama T et al. Leprosy as a model of immunity. Future Microbiol 2014; 9: 43-54
• 60 Pattnaik S. Leprosy elimination: Battle won, but the war remains. Natl Med J India 2013; 26: 57-58